Formulation and evaluation of dexlansoprazole extended-release tablet
Department of Quality Assurance, Vidyabharati College of Pharmacy, Amravati, (MH), Pin 444602 India.
Research Article
GSC Biological and Pharmaceutical Sciences, 2021, 17(03), 191–197.
Article DOI: 10.30574/gscbps.2021.17.3.0352
Publication history:
Received on 06 November 2021; revised on 18 December 2021; accepted on 20 December 2021
Abstract:
Dexlansoprazole (DSP) is a proton pump inhibitor, it used to treat GERD and ulcer colitis. DSP works by decreasing the volume of acid in the stomach. DSP is an acid-labile medication that may be destroyed in the stomach's acidic pH. A coating technique was used to postpone drug release in the stomach, which can extend pharmacological activity. Shellac can be used to develop the sustain release tablet of dexlansoprazole as retardation of the drug (dexlansoprazole) was observed in the acidic pH of the stomach, and hence a sustain coated dexlansoprazole tablet was prepared and evaluated. The coating's primary function is to allow for the delayed, immediate, and prolonged delayed release of DSP. DSP coating with different polymers inhibits faster degradation in the acidic pH of the stomach, therefore increasing pharmacological action. DSP coating with different polymers inhibits fast degradation in the stomach's acidic pH, enhancing pharmacological action. The major function of the coating is to enable for the delayed, immediate, and prolonged delayed release of DSP. DSP coating with different polymers inhibits fast breakdown in the stomach's acidic pH, enhancing pharmacological action.
Keywords:
Dexlansoprazole; Gastroesophageal reflux disease; Proton pump inhibitor; Sustain release tablet
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
